The low-end of the black hole mass function at cosmic dawn

Understanding the formation and growth of supermassive black holes (SMBHs) at high redshift represents a major challenge for theoretical models. In this work we investigate the early evolution of the first SMBHs by constraining their distribution in mass and luminosity at $z > 4$. In particular, we focus on the poorly explored low-mass end of the nuclear black hole (BH) distribution down to $z \simeq 4$, and explore its connection with the nature of the first BH seeds and the processes governing their mass growth. To this aim, we have developed CAT (Cosmic Archaeology Tool), a new semi-analytic model that describes the formation of the first stars and black holes in a self-consistent way and follows the co-evolution of nuclear BHs and their host galaxies for a representative population at $z > 4$. We find that current observational constraints favour models where the growth of BH seeds is Eddington limited and occurs at the Bondi-Hoyle-Lyttleton rate or where super-Eddington accretion occurs via a slim disk during gas rich galaxy mergers. The main difference between these two model variants lies at the low-end of the predicted mass and luminosity functions at $4 \le z \le 6$, where a clear gap appears in the first model, reflecting the stunted growth of light BH seeds formed as remnants of the first stars. Detecting this signature will be extremely challenging even for the future generation of space observatories, such as JWST, Athena and Lynx

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

IntroductionImmunocompromised patients have been shown to have an impaired immune response to COVID-19 vaccines.MethodsHere we compared the B-cell, T-cell and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus after the fourth dose of mRNA COVID-19 vaccines in patients with hematological malignancies (HM, n=71), solid tumors (ST, n=39) and immune-rheumatological (IR, n=25) diseases. The humoral and T-cell responses to SARS-CoV-2 vaccination were analyzed by quantifying the anti-RBD antibodies, their neutralization activity and the IFN-γ released after spike specific stimulation.ResultsWe show that the T-cell response is similarly boosted by the fourth dose across the different subgroups, while the antibody response is improved only in patients not receiving B-cell targeted therapies, independent on the pathology. However, 9% of patients with anti-RBD antibodies did not have neutralizing antibodies to either virus variants, while an additional 5.7% did not have neutralizing antibodies to Omicron BA.2, making these patients particularly vulnerable to SARS-CoV-2 infection. The increment of neutralizing antibodies was very similar towards Omicron BA.2 and WT virus after the third or fourth dose of vaccine, suggesting that there is no preferential skewing towards either virus variant with the booster dose. The only limited step is the amount of antibodies that are elicited after vaccination, thus increasing the probability of developing neutralizing antibodies to both variants of virus.DiscussionThese data support the recommendation of additional booster doses in frail patients to enhance the development of a B-cell response directed against Omicron and/or to enhance the T-cell response in patients treated with anti-CD20

Atrioventricular node ablation and pacing for atrial tachyarrhythmias: A meta-analysis of postoperative outcomes

Atrioventricular node ablation (AVNA) and pacemaker (PM) is performed in symptomatic atrial fibrillation (AF) unresponsive to medical treatment and percutaneous ablation. This meta-analysis evaluated results after AVNA and PM

Leaflet kinematics after the Yacoub and Florida-sleeve operations: results of an in vitro study

The Florida-sleeve is a valve-sparing technique that causes minimal interference to leaflet kinematics and aortic root dynamism. The aim of this in vitro study was to evaluate the effects of the Florida-sleeve and Yacoub techniques on aortic leaflet kinematics

Cardiovascular events and intensity of treatment in polycythemia vera

Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial